Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | APLNR | P35414 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7682664 | 0.81 | ALDH1A1 (0.38) | MAPK1USP2ALDH1A1MAPTHPGD | |
| SCHEMBL6688426 | 0.81 | DGAT1 (0.37) | DGAT1CYP2D6HDAC3HDAC1HDAC2 | |
| SCHEMBL21935444 | 0.81 | APLNR (0.31) | APLNR | |
| SCHEMBL494582 | 0.79 | DGAT1 (0.41) | DGAT1CYP2D6HDAC3HDAC1HDAC2 | |
| SCHEMBL27639930 | 0.79 | HDAC3 (0.38) | DGAT1CYP2D6HDAC3HDAC1HDAC2 | |
| SCHEMBL3228869 | 0.79 | TSHR (0.46) | DGAT1CA2CA12CA14MAPK1 | |
| SCHEMBL2173720 | 0.77 | TSHR (0.42) | DGAT1CYP2D6HDAC3HDAC1HDAC2 | |
| SCHEMBL16229307 | 0.77 | DGAT1 (0.34) | DGAT1CYP2D6HDAC3HDAC1HDAC2 | |
| SCHEMBL4158073 | 0.77 | DGAT1 (0.34) | DGAT1CYP2D6HDAC3HDAC1HDAC2 | |
| SCHEMBL13907508 | 0.77 | APLNR (0.36) | DGAT1CYP2D6HDAC3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4354855-A | Motor fuel | CHEVRON RESEARCH COMPANY (US) | 1982-10-19 | — | — | US | claimed |
| US-20240018156-A1 | SPIROCYCLIC COMPOUNDS | C4 THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20230357180-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230279023-A1 | N/O-Linked Degrons and Degronimers for Protein Degradation | C4 THERAPEUTICS, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| CN-108026072-A | Substituted oxopyridine derivatives | 拜耳制药股份公司 | 2018-05-11 | — | — | CN | disclosed |
| US-9598432-B2 | 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents | RIGEL PHARMACEUTICALS, INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-9284316-B2 | Substituted fused pyrimidine compounds | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2016-03-15 | — | — | US | disclosed |
| US-20150087643-A1 | Substituted Fused Pyrimidine Compounds | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2015-03-26 | — | — | US | disclosed |
| US-20150011002-A1 | 2,4-Pyrimidinediamine Compounds And Uses As Anti-Proliferative Agents | RIGEL PHARMACEUTICALS, INC. (US) | 2015-01-08 | — | — | US | disclosed |
| US-8859566-B2 | Substituted fused pyrimidine compounds | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2014-10-14 | — | — | US | disclosed |
| EP-1687250-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE 3-(4-HYDROXYPHENYL)PROPIONIC ACIDS | Takasago International Corporation (JP) | 2006-08-09 | — | — | EP | disclosed |
| EP-1020451-B1 | ANILIDE COMPOUNDS AND DRUGS CONTAINING THE SAME | KOWA CO (JP) | 2005-06-15 | — | — | EP | disclosed |
| WO-2005051882-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE 3-(4-HYDROXYPHENYL)PROPIONIC ACIDS | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2005-06-09 | — | — | WO | disclosed |
| US-6797717-B2 | ACYL COENZYME A CHOLESTEROL ACYLTRANSFERASE (ACAT) INHIBITORS | KOWA COMPANY, LTD. (JP) | 2004-09-28 | — | — | US | disclosed |
| US-20030087928-A1 | Novel anilide compounds and drugs containing the same | KOWA COMPANY, LTD., JAPAN | 2003-05-08 | — | — | US | disclosed |
| US-20020099074-A1 | Novel anilide compounds and drugs containing the same | KOWA COMPANY, LTD.,JAPAN | 2002-07-25 | — | — | US | disclosed |
| US-6362208-B1 | ANTICHOLESTEROL AGENT | KOWA COMPANY, LTD. (JP) | 2002-03-26 | — | — | US | disclosed |
| EP-1020451-A1 | NOVEL ANILIDE COMPOUNDS AND DRUGS CONTAINING THE SAME | Kowa Co., Ltd. (JP) | 2000-07-19 | — | — | EP | disclosed |
| US-4354855-A | Motor fuel | CHEVRON RESEARCH COMPANY (US) | 1982-10-19 | — | — | US | disclosed |
| US-4354855-A | Motor fuel | CHEVRON RESEARCH COMPANY (US) | 1982-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087928-A1 | Novel anilide compounds and drugs containing the same | ACAT1, ACAT2, LCAT | DGAT1 75/4885CYP2D6 175/4885HDAC3 441/4885 |
| US-20240018156-A1 | SPIROCYCLIC COMPOUNDS | CRBN, XIAP, RBX1 | DGAT1 4308/4885CYP2D6 4425/4885HDAC3 1330/4885 |
| US-20020099074-A1 | Novel anilide compounds and drugs containing the same | SOAT1, SOAT2, LCAT | DGAT1 154/4885CYP2D6 130/4885HDAC3 476/4885 |
| US-20150011002-A1 | 2,4-Pyrimidinediamine Compounds And Uses As Anti-Proliferative Agents | MKI67, TYMP, PCNA | DGAT1 2225/4885CYP2D6 3385/4885HDAC3 2691/4885 |
| US-20230357180-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | STUB1, MDM2, USP30 | DGAT1 4127/4885CYP2D6 2989/4885HDAC3 2828/4885 |
| US-20230279023-A1 | N/O-Linked Degrons and Degronimers for Protein Degradation | CRBN, CBL, STUB1 | DGAT1 3439/4885CYP2D6 4725/4885HDAC3 2737/4885 |
| US-20150087643-A1 | Substituted Fused Pyrimidine Compounds | ADORA2A, ADORA1, ADORA3 | DGAT1 2073/4885CYP2D6 1975/4885HDAC3 2403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.